Allogeneic stem-cell transplantation in patients with AML and MDS using myeloablative versus reduced-intensity doses of intravenous busulfan (Busulfex): The role of dose intensity
Open Access
- 28 February 2005
- journal article
- abstracts
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 11 (2) , 59
- https://doi.org/10.1016/j.bbmt.2004.12.178
Abstract
No abstract availableKeywords
This publication has 0 references indexed in Scilit: